Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

What Is Going On With These Four Stocks On The Move?

Page 1 of 2

Shares of General Electric Company (NYSE:GE), PTC Therapeutics, Inc. (NASDAQ:PTCT), American Airlines Group Inc (NASDAQ:AAL) and Spirit Airlines Incorporated (NASDAQ:SAVE) are trending, as investors digest various pieces of news related to the companies. Let’s take a closer look at the catalysts causing their price changes today and see if the smart money tracked by Insider Monkey disagrees with the market on any of them.


We pay attention to hedge funds’ moves because our research has shown that hedge funds are extremely talented at picking stocks on the long side of their portfolios. It is true that hedge fund investors have been underperforming the market in recent years. However, this was mainly because hedge funds’ short stock picks lost a ton of money during the bull market that started in March 2009. Hedge fund investors also paid an arm and a leg for the services that they received. We have been tracking the performance of hedge funds’ 15 most popular small-cap stock picks in real time since the end of August 2012. These stocks have returned 102% since then and outperformed the S&P 500 Index by around 53 percentage points (see the details here). That’s why we believe it is important to pay attention to hedge fund sentiment; we also don’t like paying huge fees.

General Electric Company (NYSE:GE) is up by 1.8% after beating earnings expectations but missing revenue estimates. For its third quarter, the company earned an adjusted $0.29 per share on revenues of $27.90 billion, versus estimates of $0.26 in EPS on revenues of $28.59 billion. The industrial division’s margins jumped by 1% and its outlook is strong, with the company reiterating its previous earnings forecast. At a forward P/E of 18.3 and with a dividend yield of 3.28%, General Electric’s shares look attractive, particularly as the U.S economy picks up steam and management uses its GE Capital sale proceeds to buy back tens of billions of dollars worth of stock over the next three years. Management expects to buy back as much as 7% of the float by the end of November.

Many hedge funds from our database also own shares of General Electric. Of the 730 funds in our database, 70 of them held $3.72 billion worth of the company’s shares at the end of June, up from 62 funds with $3.13 billion in shares a quarter earlier. However, they still held just 1.4% of the float. Ken Fisher‘s Fisher Asset Management upped its stake by 2% on the quarter to 30.71 million shares, while Nelson Peltz’s Trian Partners has recently bought a $2.5 billion stake in the company (see details). Bill Ackman’s Pershing Square spent a lot of time considering buying a stake but decided against it because it wasn’t cheap enough.

Follow General Electric Co (NYSE:GE)
Trade (NYSE:GE) Now!

PTC Therapeutics, Inc. (NASDAQ:PTCT) is up by 2.46% on strong volume after releasing the results of a phase 3 trial of Translarna yesterday, an oral protein restoration therapy for the treatment of nonsense mutation Duchenne muscular dystrophy. The drug did not meet the primary endpoint, but showed benefits over a placebo on secondary and tertiary endpoints. From the press release:

In the overall intent-to-treat study population, the primary endpoint of change from baseline in the 6-minute walk test (6MWT) demonstrated a 15 meter benefit (p=0.213), which was not statistically significant. A highly significant benefit of 47 meters (p=0.007) was demonstrated in the pre-specified patient population of 300-400 meters at baseline as measured by the 6MWT, which is in line with the Company’s prior experience in its Phase 2b trial and consistent with the evolving understanding of the 6MWT. Importantly, no patients in this group lost ambulation (0/47) versus four patients in the placebo group (4/52). Translarna showed a benefit over placebo across key secondary and tertiary endpoints, including timed function tests (10 meter Run/Walk, 4 Stair Climb, 4 Stair Descend) and the North Star Ambulatory Assessment test.

Follow Ptc Therapeutics Inc. (NASDAQ:PTCT)
Trade (NASDAQ:PTCT) Now!

On the next page, we’ll analyze why Spirit is down and why American Airlines is trending.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!